Bharat Biotech BBV152 COVAXIN®

Vaccine effectiveness against COVID-19 of any severity was 78 percent 14 or more days after dose 2. The effectiveness of vaccines against severe disease is 93%. Adults aged less than 60 years had a 79 percent efficacy rate, whereas those aged 60 and over had a 68 percent efficacy rate.

Vaccine efficacy against all variant-related COVID-19 illness was 71%, with 90% efficacy against Kappa and 65% efficacy against Delta. In light of these findings, WHO recommends using the BBV152 vaccine in accordance with the WHO Prioritization Roadmap, even if the nation contains currently recognized Variants of Concern (VOC). If new VOCs emerge that impact vaccination performance, these recommendations will be updated accordingly. There is currently no information available for Omicron.

MORE INFORMATION:
Manufacturer: Bharat Biotech International Limited (BBIL)
Number of Shots: 2 shots, less than 4 weeks apart
Type of Vaccine: Inactivated